Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07506512
PHASE3

Optimal Time Interval Between Mifepristone and Misoprostol Administration for Early Pregnancy Loss

Sponsor: University of Pennsylvania

View on ClinicalTrials.gov

Summary

A prospective cohort study to explore the optimal time interval between mifepristone and misoprostol administration for medical management of early pregnancy loss. Participants will be followed to assess treatment success, satisfaction, and side effects.

Key Details

Gender

FEMALE

Age Range

Any - Any

Study Type

INTERVENTIONAL

Enrollment

1000

Start Date

2026-07

Completion Date

2031-12

Last Updated

2026-04-01

Healthy Volunteers

No

Interventions

DRUG

200mg mifepristone and 800mg misoprostol

Participants will take 200mg of mifepristone by mouth and will be instructed to administer misoprostol any time between 4- and 24-hours post-mifepristone.